Literature DB >> 3278430

Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts.

K P Batts1, S B Moore, J D Perkins, R H Wiesner, P M Grambsch, R A Krom.   

Abstract

Among the first 52 recipients of primary liver allografts with follow-up of 2 weeks or greater, 6 patients had biopsy-confirmed vanishing bile duct syndrome (VBDS) and required retransplantation. Five of these six patients had positive lymphocyte crossmatches. Of the 46 remaining liver transplant recipients, 11 had positive crossmatches. Thus, the incidence of VBDS was 5/16 in recipients with a positive crossmatch and 1/36 in recipients with a negative crossmatch. The positive-crossmatch group was significantly more likely to develop VBDS than the negative-crossmatch group (P less than 0.004, log rank test). Additional HLA studies comparing degree of donor-recipient mismatch at the various HLA loci showed no significant difference between the groups for class I disparity. However, class II mismatch was of borderline significance (P less than 0.056). When evaluated individually, the DQ mismatch (P less than 0.04) appeared to be more important than the DR mismatch (P = NS). Our data suggest that a positive lymphocyte crossmatch and a class II mismatch, in particular HLA DQ disparity, may play an important role in the pathogenesis of VBDS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278430     DOI: 10.1097/00007890-198802000-00026

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  14 in total

1.  Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts.

Authors:  S Takaya; A Jain; A Yagihashi; K Nakamura; M Kobayashi; K Takeuchi; S Suzuki; Y Iwaki; A J Demetris; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1999-08       Impact factor: 1.066

2.  Antibody mediated rejection of human liver allografts: transplantation across ABO blood group barriers.

Authors:  A J Demetris; R Jaffe; A Tzakis; G Ramsey; S Todo; S Belle; C Esquivel; R Shapiro; A Zjako; B Markus
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

3.  The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

Authors:  A I Musat; R M Agni; P Y Wai; J D Pirsch; D F Lorentzen; A Powell; G E Leverson; J M Bellingham; L A Fernandez; D P Foley; J D Mezrich; A M D'Alessandro; M R Lucey
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

4.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

5.  Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model.

Authors:  K Nakamura; N Murase; M J Becich; T Furuya; S Todo; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

Review 6.  The biological basis of and strategies for clinical xenotransplantation.

Authors:  T E Starzl; L A Valdivia; N Murase; A J Demetris; P Fontes; A S Rao; R Manez; I R Marino; S Todo; A W Thomson
Journal:  Immunol Rev       Date:  1994-10       Impact factor: 12.988

Review 7.  The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us?

Authors:  A J Demetris; N Murase; C P Delaney; M Woan; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

8.  Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss.

Authors:  Jacqueline G O'Leary; Hugo Kaneku; Anthony J Demetris; John D Marr; S Michelle Shiller; Brian M Susskind; Glenn W Tillery; Paul I Terasaki; Göran B Klintmalm
Journal:  Liver Transpl       Date:  2014-01-02       Impact factor: 5.799

9.  Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features.

Authors:  Jacqueline G O'Leary; S Michelle Shiller; Christopher Bellamy; Michael A Nalesnik; Hugo Kaneku; Linda W Jennings; Kumiko Isse; Paul I Terasaki; Göran B Klintmalm; Anthony J Demetris
Journal:  Liver Transpl       Date:  2014-10       Impact factor: 5.799

10.  Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect?

Authors:  B H Markus; R J Duquesnoy; R D Gordon; J J Fung; M Vanek; G Klintmalm; C Bryan; D Van Thiel; T E Starzl
Journal:  Transplantation       Date:  1988-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.